OS Therapies

OS Therapies is a clinical-stage therapeutic company committed to developing treatments for Osteosarcoma (OS) and other solid tumors. Their mission is to address the significant unmet need for new treatments for bone cancer in both children and adults, especially as there have been no new treatments for OS in over 30 years. The company is currently focused on the development of OST-HER2, a lead candidate for HER-2 Osteosarcoma, and OST-tADC, a next-generation Antibody Drug Conjugate (ADC) platform technology targeting Ovarian, Lung, and Pancreatic cancer.

OS Therapies boasts a robust pipeline of potential treatments, including OST-HER2 for Osteosarcoma and OST-tADC for other solid tumors. The company is actively conducting clinical trials, including a Phase 2b trial for OST-HER2 in patients with resected, recurrent Osteosarcoma. They are also developing a tunable drug conjugate (tADC) technology that aims to improve both the efficacy and safety of cancer treatments. OS Therapies is dedicated to advancing innovative therapies that can improve and extend the lives of patients suffering from these challenging cancers.

OS Therapies is a clinical-stage therapeutic company dedicated to developing and commercializing innovative treatments for Osteosarcoma and other solid tumors, particularly those with high recurrence rates. Recognizing the lack of new treatments for Osteosarcoma in over 30 years, OS Therapies aims to address this significant unmet need by identifying lead candidates and advancing them through clinical development, regulatory approval, and ultimately, commercialization.

OS Therapies promotes a culture of innovation, collaboration, and dedication to finding new treatments for Osteosarcoma and other solid tumors. They foster a sense of community, emphasizing the importance of working together to achieve their goal of providing hope and better treatments to patients. Their emphasis on "looking for the light" and honoring the courage of those who have fought against Osteosarcoma, highlights their commitment to compassion and making a real difference in the lives of those impacted by the disease.